Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs

Archives of Internal Medicine

Volumn 158, Issue 1, 1998, Pages 33-39

  García Rodríguez, Luis Alberto ^a   Cattaruzzi, Chiara ^b,e   Troncon, Maria Grazia ^c   Agostinis, Luisa ^d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c Regional Health Directorate   (Italy)

^d Insiel   (Italy)

^e Azienda Ospedaliera   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ARTICLE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; KETOROLAC; KETOROLAC TROMETHAMINE; MALE; MIDDLE AGED; RISK; RISK FACTORS; TIME FACTORS; TOLMETIN; TROMETHAMINE;

EID: 0002656782     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.1.33     Document Type: Article

References (14)

1. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995;44:1-10.
2. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiply, but do they add up? BMJ. 1990;300:278-284.
3. Bollini P, García Rodríguez LA, Pérez Gutthann S, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of NSAIDs on upper gastrointestinal pathology. Arch Intern Med. 1992;152:1289-1295.
4. Lewis S. Ketorolac in Europe. Lancet. 1994;343:784.
5. Henry D, Lim LL-Y, García Rodríguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563-1566.
6. Legault C, Furberg CD, Wagenknecht LE, et al. Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke. 1996;27: 593-598.
7. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 1996;347:1061-1065.
8. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
9. García Rodríguez LA, Jick H. The risk of upper gastrointestinal bleeding and/or perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
10. Norusis MJ. SPSS Advanced Statistics Users's Guide. Chicago, III: SPSS Inc; 1990.
11. Pérez Gutthann S, García Rodríguez LA, Raiford DS. Individual NSAIDs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 1997;8:18-24.
12. Strom BL, Berlin JA, Kinman MA, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. JAMA. 1996;275:376-382.
13. Traversa G, Walker AM, Menniti F, et al. Gastroduodenal toxicity of different non-steroidal antiinflammatory drugs. Epidemiology. 1995;6:49-54.
14. Wagenknecht LE, Furberg CD, Hammon JW, Legault C, Troost BT. Surgical bleeding: an unexpected effect of a calcium antagonist. BMJ. 1995;310:776-777.